Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month […]
Related Keywords
United States , Piper Sandler , Money Concepts Capital Corp , Goldman Sachs Group , Comerica Bank , Needham Company , Barclays , Tower Group , Assetmark Inc , Revance Therapeutics Inc , Advisor Group Holdings Inc , Nasdaq , Revance Therapeutics , Get Free Report , Marketbeat Ratings , Concepts Capital Corp , Advisor Group Holdings , Group Holdings , Get Free , Revance Therapeutics Daily , Nasdaq Rvnc , Rvnc , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.